The DOI matches its Crossref record.
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An ongoing phase 1–2 study of adagrasib that involves patients with KRASG12C-mutant cancer has shown an objective response rate of 45% among patients with NSCLC11,12 and 17% among those with colorectal cancer.13”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [13]
In the citing paper
“initial monotherapy response rates for both drugs in colorectal cancer (CRC) are lower than in NSCLC.”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [26]
In the citing paper
“In CRC, RTK dependency and signaling rebound kinetics have been identified as potential mechanisms underlying resistance to KRASG12C inhibition (23, 26, 27).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [26]
In the citing paper
“Learnings from KRASG12C inhibitors have been limited so far with only case reports of responses, since KRASG12D and KRASG12V represent the majority of KRAS mutations occurring in about 65% of all PDAC cases, while G12C mutations are very rare with 1.1% (23, 26).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [26]
In the citing paper
“In KRASG12C-mutated CRC, sotorasib showed an initial objective response rate of 7% (3 of 42 patients), while treatment with adagrasib yielded a preliminary response rate of 17% (3 of 18 patients) (23, 26).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [26]
Citations
Cites
Still being checked.
Cited by
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Self-citationExpanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Treatment landscape of metastatic pancreatic cancer
De Dosso, S., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 209
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Metadata
- Authors
- Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., & Weiss, J.
- Affiliations
- Sarah Cannon (US)
- University of California, Irvine (US)
- Mary Crowley Cancer Research Center (US)
- Henry Ford Hospital (US)
- South Texas Accelerated Research Therapeutics (US)
- University of Wisconsin–Madison (US)
- Mirati Therapeutics (United States) (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 138
- Pages
- S2
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W3097219677
- Cited by
- 77
- References
- 0
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 22 · 2021: 31 · 2020: 1
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- European Journal of Cancer (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- adagrasib, KRAS G12C mutation, colorectal cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, KRAS inhibitors, irreversible covalent inhibitors, desmoplasia, drug safety, drug activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. https://app.cochat.ai/papers/10.1016/s0959-8049(20)31077-7
- The paper
- Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., & Weiss, J. (2020). KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(20)31077-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.